The AKAP7 Knockout HeLa Polyclonal Cells product comprises a heterogeneous population of HeLa cells subjected to CRISPR/Cas9-mediated disruption of the AKAP7 gene, resulting in a polyclonal pool of cells with targeted loss-of-function mutations. This knockout model disrupts the expression of A-kinase anchoring protein 7 (AKAP7), enabling researchers to dissect the compartmentalized cAMP/PKA signaling networks that rely on AKAP7-mediated scaffolding. The polyclonal format provides a robust and cost-effective tool for loss-of-function studies without the selective pressures of single-cell cloning, making it suitable for pooled functional assays and initial target validation.
HeLa cells, derived from a cervical adenocarcinoma of a 31-year-old African American patient, are an immortalized human epithelial cell line with integrated HPV18 sequences, characterized by genomic instability and aneuploidy. As a widely used cancer biology model, HeLa cells offer a well-established system for studying cellular processes, including signal transduction, proliferation, and apoptosis. Their robust growth and ease of manipulation make them ideal for generating knockout populations, though their transformed nature requires careful interpretation of data when extrapolating to non-cancerous contexts. The AKAP7 disruption in this background allows investigation of AKAP7 function within the context of aberrant signaling common in cancer cells.
AKAP7 functions as a molecular scaffold that anchors the protein kinase A (PKA) holoenzyme, via regulatory subunits such as RII??, to specific subcellular compartments, thereby ensuring localized and efficient phosphorylation of downstream targets. Upstream, AKAP7 integrates signals from cAMP produced upon activation of receptors such as beta-adrenergic receptors, and its activity is modulated by phosphodiesterases and protein phosphatases that shape cAMP gradients. Once anchored, PKA phosphorylates critical substrates including L-type calcium channels, potassium channels, and phospholamban, directly impacting ion channel regulation, cardiac repolarization, and synaptic transmission. Transcription factors like CREB further mediate longer-term responses, linking AKAP7 scaffolding to gene expression programs.
In HeLa cells, AKAP7 knockout provides a unique platform to dissect PKA anchoring mechanisms outside their canonical cardiac and neuronal roles, exploring instead how compartmentalized cAMP signaling influences epithelial cancer cell behavior. Given HeLa cells’ genomic instability and reliance on altered signaling pathways, AKAP7 disruption may reveal its involvement in processes such as cell cycle control, migration, or drug sensitivity. The model allows researchers to attribute specific functional outcomes to AKAP7-dependent PKA localization by comparing wild-type and knockout populations, thereby clarifying the role of AKAP7 in maintaining signaling microdomains that could be dysregulated in cervical adenocarcinoma.
Researchers can employ this AKAP7 polyclonal knockout cell population in diverse applications, such as investigating the spatial regulation of cAMP dynamics using FRET-based biosensors, performing co-immunoprecipitation to map altered PKA interactomes, or conducting patch-clamp electrophysiology to assess changes in ion channel activity. High-throughput drug screening for modulators of AKAP7-PKA interactions is feasible, with relevance to Long QT syndrome and cardiac arrhythmia research, even in a non-cardiac background. Standard techniques like Western blotting, immunofluorescence, and RT-qPCR enable robust validation of knockout efficiency and downstream effects. For detailed inquiries and support, please contact Ascent Research.
